UPCC 28422 An Open-Label, Phase I Study To Evaluate The Safety, Pharmacokinetics And Preliminary Anti-Tumor Activity Of Ro7227166 (A Cd19 Targeted 4-1bb Ligand) In Combination With Obinutuzumab And In Combination With Glofitamab Following A Pre-Treatme

Brief description of study

Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 852167

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).